StreetAlpha.app
Home › Stocks › PGEN

Precigen, Inc. (PGEN)

Healthcare
$4.29
▼ −0.23%
LAST CLOSE · NOV 17

Precigen is a biopharmaceutical company that develops gene medicines for patients with cancer, autoimmune and infectious diseases. It last closed at $4.29 on Nov 17, down 0.23% on the day. The average 12-month price target from 2 analysts is $11.50 (+168.1% from the last close), with a high of $12.00 and a low of $11.00. In the past 30 days there were 1 dark pool print totaling $126K, the largest $126K.

AI Auto Pilots
Is PGEN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$156.9M
Net income
$24.4M
15.6% margin
EPS (diluted)
$0.11
Free cash flow
−$74.3M
−47.4% margin
Valuation
Market cap
$1.5B
358.5M shares
P/E
39.0
Price over 12 month EPS
Price to sales
9.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$15.0M
At Sep 30
Debt
$94.3M
At Sep 30
Shareholder equity
$83.8M
Shares outstanding
358.5M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $14.3M$14.3MFY2021FY2022: $26.9M$26.9MFY2022FY2023: $6.2M$6.2MFY2023FY2024: $3.9M$3.9MFY2024FY2025: $9.7M$9.7MFY2025

From PGEN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated PGEN in the past 90 days, not enough for a consensus
Average 12-month target
$11.50
▲ 168.1% upside

Based on 2 analysts who set a price target on PGEN in the past 90 days. The average target is $11.50, with a high of $12.00 and a low of $11.00, compared with the last close of $4.29.

$3$6$9$13PAST 23 TRADING DAYS12-MONTH TARGETSHIGH $12AVG $11.50LOW $11Jun 3LAST CLOSE+12 MO$3$6$9$13PAST 23 DAYSTARGETSHIGH $12AVG $11.50LOW $11Jun 3LAST CLOSE+12 MO
Highest target$12.00
Average target$11.50
Lowest target$11.00
Latest rating changes
B. Riley SecuritiesTarget lowered
Nov 16Buy$12 → $11
CitizensMaintained
Nov 5Buy$12
B. Riley SecuritiesInitiated
Sep 25Buy$12
HC Wainwright & Co.Target raised
Aug 5Buy$14 → $18
HC Wainwright & Co.Maintained
May 28Buy$14
DateFirmActionRatingPrice target
Nov 16B. Riley SecuritiesTarget loweredBuy$12 → $11
Nov 5CitizensMaintainedBuy$12
Sep 25B. Riley SecuritiesInitiatedBuy$12
Aug 5HC Wainwright & Co.Target raisedBuy$14 → $18
May 28HC Wainwright & Co.MaintainedBuy$14
Loading…

Technical Analysis

PGEN · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 25% below its 20 day and 55% below its 50 day average. It is 23% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot at $4.28, and the nearest resistance the Pivot R1 at $4.36.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.8%/day
Key levels
$8.9852 week high+109.3%
$6.6350 day average+54.5%
$6.43100 day average+49.9%
$5.3520 day average+24.7%
$5.28200 day average+23.1%
$4.68Swing high (May 28)+9.1%
$4.36Pivot R1+1.6%
$4.29Last close
$4.28Pivot−0.2%
$4.20Pivot S1−2.1%
$4.11Swing low (May 27)−4.2%
$3.0452 week low−29.1%
Indicators
RSI (14)32.09Weak, oversold below 30Neutral
MACD-0.69Below its signal lineBearish
Stochastic14.5Near the bottom of its rangeOversold
ADX (14)29.5Trending down
Williams %R-88.3Oversold below −80, overbought above −20Oversold
CCI (20)-85.8Oversold below −100, overbought above 100Neutral
Rate of change−18.3%Change over 10 sessionsBearish
ATR (14)$0.46Typical daily range, 10.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PGEN

What happened before

See how PGEN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PGEN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PGEN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PGEN in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$126K
Largest print
$126K
Loading…

PGEN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲142 buying vs 73 selling
  • ▲Held by funds +0.8 pts
  • ▲Funds holding +34
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding246212+16.0%
In funds' top 1053+66.7%
Held by funds40.0%39.2%+0.8 pts
New / increased54 / 8836 / 84+18.3%
Reduced / sold out52 / 2145 / 280.0%
Put/call ratio0.061.08−94.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PGEN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PGEN is in one of them and how their past PGEN trades turned out.

PGEN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PGEN in an article yet. Here's the latest on the wider market.

About Precigen

Precigen is a biopharmaceutical company based in Germantown, Maryland, that develops medicines for patients with hard to treat diseases. Its main focus areas are cancer, autoimmune disorders and infectious diseases. Its approved product, Papzimeos, is an immunotherapy for adults with recurrent respiratory papillomatosis, a rare disease caused by HPV infection. The company also develops cell and gene therapies that are in clinical trials or at earlier research stages.

Headquarters
Germantown, MD
Founded
1998